Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of S-892216-LAI in Healthy Adults
NCT07093580Phase 1Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of S-892216-LAI (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Number of Participants With Treatment-emergent Adverse Events at Day 448. Started Jul 2025; status: recruiting.
02
Drugs
S-892216-LAI
Beyond the preview
Go deeper on NCT07093580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093580.